Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jul 11, 2023 10:48am
113 Views
Post# 35535362

RE:RE:TIGIT class of checkpoint inhibitors fails with Keytruda

RE:RE:TIGIT class of checkpoint inhibitors fails with Keytruda July 11, 2023 - Novaartis retreats from TIGIT - hands Tigit candidate back to Chinese company BiGene.

In a SEC filing today, the Chinese drugmaker said the two companies agreed yesterday to mutually terminate the option agreement for ociperlimab with immediate effect. As a result, BeiGene’s Swiss unit will regain full global rights to the drug.


 The end of the agreement means the Big Pharma will no longer proceed with a phase 3 study of ociperlimab in non-small cell lung cancer (NSCLC) or its phase 2 study of the drug in triple negative breast cancer, the spokesperson added. 

Once hailed as the future of immuno-oncology, the hopes for TIGITs were thrown into doubt by the high-profile phase 3 failures of Roche’s tiragolumab last year. 


https://www.fiercebiotech.com/biotech/novartis-retreats-tigit-handing-300m-candidate-back-beigene

 

<< Previous
Bullboard Posts
Next >>